Scalper1 News
July could see 19 biotechs go public and currently represent 50% of the 34 IPOs scheduled for the next two weeks, according to Renaissance Capital. It’s also a sharp spike from the 38 biotech initial public offerings in the first half of the year. Upcoming biotech IPOs include several that are focused on the eyes, ears and nose. They include Ocular Therapeutix (OCUL), a developer of injectable sustained release therapies that treat various eye Scalper1 News
Scalper1 News